Last reviewed · How we verify

Cyclosporine/placebo-cyclosporine

Hvidovre University Hospital · FDA-approved active Small molecule

Cyclosporine/placebo-cyclosporine is a Calcineurin inhibitor Small molecule drug developed by Hvidovre University Hospital. It is currently FDA-approved for Organ transplant rejection prevention, Autoimmune and inflammatory conditions (context-dependent based on trial indication).

Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines.

Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines. Used for Organ transplant rejection prevention, Autoimmune and inflammatory conditions (context-dependent based on trial indication).

At a glance

Generic nameCyclosporine/placebo-cyclosporine
SponsorHvidovre University Hospital
Drug classCalcineurin inhibitor
TargetCalcineurin (protein phosphatase 2B)
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Cyclosporine binds to cyclophilin and inhibits calcineurin phosphatase, preventing dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the production of interleukin-2 and other cytokines essential for T-cell proliferation and immune response. The placebo-controlled formulation in this study allows for comparison of cyclosporine's immunosuppressive effects against no active treatment.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cyclosporine/placebo-cyclosporine

What is Cyclosporine/placebo-cyclosporine?

Cyclosporine/placebo-cyclosporine is a Calcineurin inhibitor drug developed by Hvidovre University Hospital, indicated for Organ transplant rejection prevention, Autoimmune and inflammatory conditions (context-dependent based on trial indication).

How does Cyclosporine/placebo-cyclosporine work?

Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines.

What is Cyclosporine/placebo-cyclosporine used for?

Cyclosporine/placebo-cyclosporine is indicated for Organ transplant rejection prevention, Autoimmune and inflammatory conditions (context-dependent based on trial indication).

Who makes Cyclosporine/placebo-cyclosporine?

Cyclosporine/placebo-cyclosporine is developed and marketed by Hvidovre University Hospital (see full Hvidovre University Hospital pipeline at /company/hvidovre-university-hospital).

What drug class is Cyclosporine/placebo-cyclosporine in?

Cyclosporine/placebo-cyclosporine belongs to the Calcineurin inhibitor class. See all Calcineurin inhibitor drugs at /class/calcineurin-inhibitor.

What development phase is Cyclosporine/placebo-cyclosporine in?

Cyclosporine/placebo-cyclosporine is FDA-approved (marketed).

What are the side effects of Cyclosporine/placebo-cyclosporine?

Common side effects of Cyclosporine/placebo-cyclosporine include Nephrotoxicity/renal dysfunction, Hypertension, Tremor, Gingival hyperplasia, Hirsutism, Headache.

What does Cyclosporine/placebo-cyclosporine target?

Cyclosporine/placebo-cyclosporine targets Calcineurin (protein phosphatase 2B) and is a Calcineurin inhibitor.

Related